While we acknowledge that this is an in vitro system, frequently patients present with co-infections (bacterial and fungal) and it is therefore very plausible that antimicrobial synergy may occur in the clinical setting leading to higher levels of MMP-7 and may explain a lack of response to mTOR inhibition. The gene discussed is MTOR; the disease is coinfection.